11:07:00 EST Sun 16 Feb 2025
Enter Symbol
or Name
USA
CA



Q:AZN - ASTRAZENECA PLC SPON ADR EACH REP 0.50 ORD SHS - https://www.astrazeneca.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AZN - Q0.273.59·74.353.673.58-0.878-1.25,783.7425,16332,98674.335  74.58  73.450187.67  61.7719:52:3511:1015 min RT 2¢

Recent Trades - Last 10 of 32986
Time ETExPriceChangeVolume
19:52:35Q73.59-0.8614
19:48:49Q73.60-0.8527
19:46:41Q73.59-0.865
19:07:07Q73.60-0.8540
18:29:15Q73.5325-0.91751
18:29:15Q73.5325-0.91751
18:25:34Q73.503-0.94733
18:13:49Q73.84-0.6122
17:43:37Q73.93-0.521
17:43:27Q73.52-0.931

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-02-14 11:10U:AZNNews ReleaseIMFINZI(TM) (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
2025-02-06 07:00U:AZNNews ReleaseAstraZeneca's Full Year and Q4 2024 results
2025-01-27 18:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
2025-01-23 14:31U:AZNNews ReleaseAstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery
2025-01-22 08:30U:AZNNews ReleaseDemand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
2025-01-17 17:35U:AZNNews ReleaseDATROWAY(TM) (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
2025-01-17 07:00U:AZNNews ReleaseCALQUENCE(TM) (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
2025-01-13 07:00U:AZNNews ReleaseDatopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2024-12-26 09:00U:AZNNews ReleaseAchievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
2024-12-18 09:05U:AZNNews ReleaseAlexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform
2024-12-11 10:15U:AZNNews ReleaseLYNPARZA(TM) (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
2024-12-09 07:00U:AZNNews ReleaseDatopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2024-12-08 11:00U:AZNNews ReleaseFixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
2024-12-06 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer
2024-12-05 07:13U:AZNNews ReleaseIMFINZI(TM) (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
2024-11-25 07:00U:AZNNews ReleaseTRUQAP(TM) (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
2024-11-20 07:30U:AZNNews ReleaseAstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
2024-11-18 16:01U:AZNNews ReleaseGRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
2024-11-12 07:00U:AZNNews ReleaseAstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
2024-11-12 07:00U:AZNNews ReleaseAstraZeneca's 9M and Q3 2024 results